Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
Lundbeck's idalopirdine is a so-called 5-HT6 antagonist and is similar to another pill, called intepirdine, being developed by U.S. biotech firm Axovant Sciences.
